트렘피아 세계 시장은 2024년에 37억 8,000만 달러로 평가되었고, CAGR 7.59%를 나타낼 전망이며, 2030년에는 58억 7,000만 달러에 이를 것으로 예측됩니다.
트렘피어 세계 시장은 건선, 건선성 관절염 등 만성 자가면역질환 관리에 있어 표적 생물학적 치료제에 대한 수요가 증가함에 따라 꾸준한 성장세를 보이고 있습니다. IL-23 억제제인 트렘피어는 높은 유효성, 우수한 안전성 프로파일, 간편한 투약 스케줄로 환자의 순응도와 치료 성적을 향상시켜 큰 주목을 받고 있습니다. 전 세계적으로 이러한 질환의 유병률이 증가하고 있으며, 환자와 의료 전문가들 사이에서 표적 면역 치료의 이점에 대한 인식이 높아지면서 시장 확대에 기여하고 있습니다. 제약사들은 다른 염증성 질환에 대한 적용을 포함하여 보다 광범위한 치료 가능성을 모색하기 위해 첨단 연구와 임상시험에 투자하고 있습니다. 중등도에서 중증의 경우 생물학적 제제를 권장하는 치료 가이드라인이 확대되면서 채택률이 더욱 높아지고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 37억 8,000만 달러 |
| 시장 규모 : 2030년 | 58억 7,000만 달러 |
| CAGR : 2025-2030년 | 7.59% |
| 급성장 부문 | 건선성 관절염(PsA) |
| 최대 시장 | 북미 |
이 시장에서는 치료 효과는 유지하면서 투여 횟수를 줄일 수 있는 지속형 생물학적 제제로의 전환이 진행되고 있으며, 이는 트렘피어의월1회 또는 분기별 투여 스케줄에 부합합니다. 생물학적 제제와 약물 전달 시스템의 끊임없는 발전은 환자의 순응도와 치료 만족도를 향상시키는 데 기여하고 있습니다. 또한, 환자 교육 개선, 치료 경로 최적화, 보험 적용 및 상환 프로그램을 통한 접근성 확대를 위해 제약사 및 의료 서비스 제공업체와의 협력도 눈에 띄게 증가하고 있습니다. 경쟁 역학은 시장 침투력 강화와 미충족 수요 대응을 위한 지속적인 제품 혁신, 파이프라인 확장, 전략적 제휴를 통해 형성되고 있습니다. 또한, 개인 맞춤형 의료에 대한 관심이 높아지면서 임상의들이 복잡한 면역 매개 질환 환자들을 위해 보다 정확하고 효과적인 치료 옵션을 찾고 있는 가운데, 트렘피아와 같은 표적 치료제의 개발이 가속화되고 있습니다.
유망한 성장 전망에도 불구하고, 세계 트렘피어 시장은 몇 가지 문제에 직면해 있습니다. 특히 중저소득 지역에서는 높은 치료비가 여전히 큰 장벽으로 작용하고 있어 환자들의 폭넓은 접근을 제한하고 있습니다. 바이오시밀러에 대한 특허 독점권 및 규제 요건으로 인해 당분간은 경쟁적인 가격 책정이 제한되고, 비용 관련 제약이 지속될 수 있습니다. 또한, 환자에 따라 치료 효과에 차이가 있어 다른 치료 전략이 필요할 수도 있습니다. 시장은 IL-17 및 TNF 억제제와 같은 유사한 경로를 표적으로 하는 다른 생물학적 제제 및 저분자 의약품과의 치열한 경쟁에 노출되어 있으며, 이는 특정 환자군에서 트렘피어의 채택에 영향을 미칠 수 있습니다. 또한, 새로운 적응증 승인은 시간이 오래 걸리고 복잡하기 때문에 시장 확대 기회가 지연될 수 있습니다. 가격 전략, 환자 지원 프로그램, 지속적인 임상 연구를 통해 이러한 과제를 해결하는 것이 예측 기간 동안 성장을 유지하는 데 매우 중요합니다.
만성 염증성 질환의 유병률 증가
높은 치료비
IL-23 억제제 도입 증가
The Global Tremfya Market was valued at USD 3.78 Billion in 2024 and is expected to reach USD 5.87 Billion by 2030 with a CAGR of 7.59%. The Global Tremfya Market is witnessing steady growth, driven by rising demand for targeted biologic therapies in managing chronic autoimmune conditions such as plaque psoriasis and psoriatic arthritis. Tremfya, an IL-23 inhibitor, has gained significant attention due to its high efficacy, favorable safety profile, and convenient dosing schedule, which enhance patient adherence and treatment outcomes. Growing prevalence of these conditions worldwide, coupled with increasing awareness among patients and healthcare professionals about the benefits of targeted immunology therapies, is contributing to the market's expansion. Pharmaceutical companies are investing in advanced research and clinical trials to explore the broader therapeutic potential of Tremfya, including its application in other inflammatory disorders. Expanding treatment guidelines that recommend biologics for moderate-to-severe cases are further boosting adoption rates.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 3.78 Billion |
| Market Size 2030 | USD 5.87 Billion |
| CAGR 2025-2030 | 7.59% |
| Fastest Growing Segment | Psoriatic Arthritis (PsA) |
| Largest Market | North America |
The market is experiencing a shift toward long-acting biologics that reduce dosing frequency while maintaining therapeutic effectiveness, aligning well with Tremfya's monthly or quarterly administration schedule. Continuous advancements in biologic drug formulation and delivery systems are supporting better patient compliance and treatment satisfaction. There is also a notable increase in collaborations between pharmaceutical manufacturers and healthcare providers to improve patient education, optimize treatment pathways, and expand access through insurance coverage and reimbursement programs. Competitive dynamics are being shaped by ongoing product innovation, pipeline expansions, and strategic partnerships aimed at enhancing market penetration and addressing unmet needs. Furthermore, the increasing focus on personalized medicine is encouraging the development of targeted therapies like Tremfya, as clinicians seek more precise and effective treatment options for patients with complex immune-mediated diseases.
Despite the promising growth prospects, the Global Tremfya Market faces several challenges. High treatment costs remain a major barrier, particularly in low- and middle-income regions, limiting broader patient access. Patent exclusivity and regulatory requirements for biosimilars may restrict competitive pricing in the near term, prolonging cost-related limitations. Some patients may also experience varying treatment responses, necessitating alternative therapeutic strategies. The market is subject to intense competition from other biologics and small molecule drugs targeting similar pathways, such as IL-17 and TNF inhibitors, which may impact Tremfya's adoption in certain patient segments. Additionally, the lengthy and complex drug approval process for new indications can delay market expansion opportunities. Addressing these challenges through pricing strategies, patient assistance programs, and continued clinical research will be crucial for sustaining growth in the forecast period.
Key Market Drivers
Rising Prevalence of Chronic Inflammatory Diseases
The rising prevalence of chronic inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis is a compelling driver for the Global Tremfya Market. In the United States, psoriasis affects approximately 3.0% of adults, translating to over 7.5 million individuals, according to data from the National Health and Nutrition Examination Survey. Among these, a significant portion go on to develop psoriatic arthritis, which impacts roughly 0.41% of the U.S. adult population, equating to nearly 912,000 adults.
Inflammatory bowel diseases (IBD), encompassing Crohn's disease and ulcerative colitis, are diagnosed in approximately 721 per 100,000 Americans, or nearly 1 in 100, as reported by the Crohn's & Colitis Foundation in a comprehensive U.S. population-based study. Strong diagnostic data reinforces the growing burden of these conditions. These diseases are often chronic and debilitating, underscoring the importance of effective long-term treatment strategies. Tremfya's targeted mechanism of selectively inhibiting the p19 subunit of interleukin-23 addresses the underlying inflammatory pathways more precisely than older systemic therapies. This precision results in favorable safety and efficacy outcomes, making Tremfya an appealing treatment for both clinicians and patients seeking better disease control and improved quality of life.
Rising obesity rates, environmental stressors, and an aging population contribute to increasing incidence and prevalence of these immune-mediated conditions. Healthcare systems emphasize early intervention to prevent disease progression, reduce flare-ups, and minimize complications such as joint damage or gastrointestinal scarring. Demand remains strong for biologics like Tremfya that offer durable remission and reduced dosing frequency. Altogether, the confluence of growing patient populations supported by robust U.S. epidemiological data and Tremfya's effective, targeted profile is fueling market momentum and positioning it as a preferred therapy in managing chronic inflammatory diseases.
Key Market Challenges
High Treatment Costs
High treatment costs remain one of the most significant challenges impacting the Global Tremfya Market. Tremfya, being a biologic therapy, involves complex manufacturing processes, stringent quality controls, and advanced biotechnology infrastructure, all of which contribute to its high price point. The expense is further amplified by research and development costs, clinical trial investments, and regulatory compliance requirements. For many patients, particularly in low- and middle-income countries, the price of Tremfya places it beyond financial reach without robust insurance coverage or government subsidy programs. Even in developed markets, patients may face high out-of-pocket expenses, co-payments, or limitations in reimbursement policies, which can result in reduced adoption rates.
Healthcare systems often prioritize cost-effectiveness, and biologics like Tremfya must demonstrate clear value over existing therapies to justify coverage. This economic barrier can lead to delayed treatment initiation, therapy discontinuation, or a preference for cheaper alternatives, even if they are less effective. Pharmaceutical companies face the challenge of balancing innovation with affordability while navigating pricing negotiations with payers. The high treatment cost issue also influences competitive dynamics, as the emergence of biosimilars or alternative biologics with lower prices could erode market share. Addressing this challenge requires strategic pricing, value-based reimbursement models, and expansion of patient assistance programs to make Tremfya more accessible.
Key Market Trends
Increasing Adoption of IL-23 Inhibitors
The increasing adoption of IL-23 inhibitors is emerging as a defining trend in the Global Tremfya Market, driven by the growing recognition of their targeted therapeutic benefits in treating chronic immune-mediated inflammatory diseases. IL-23 inhibitors, such as Tremfya, block the p19 subunit of the interleukin-23 cytokine, a critical driver of inflammation in conditions like plaque psoriasis and psoriatic arthritis. This highly specific mechanism of action offers a favorable efficacy-to-safety ratio, making these drugs an attractive option for both physicians and patients, particularly those who have experienced suboptimal responses or adverse effects with older biologic classes such as TNF-alpha inhibitors or IL-17 blockers. The extended dosing intervals associated with IL-23 inhibitors, often every eight to twelve weeks after initial loading doses, enhance treatment adherence by reducing the frequency of injections, which is a significant advantage for patients managing lifelong conditions.
Clinical trial data and real-world evidence continue to validate the long-term durability of response and low immunogenicity risk, further building confidence in this drug class. Pharmaceutical companies are also expanding the scope of IL-23 inhibitor applications into new indications such as Crohn's disease and ulcerative colitis, which could substantially broaden their market potential. As prescriber familiarity grows and healthcare systems begin to recognize their long-term cost-effectiveness due to reduced disease flare-ups and improved quality of life, the uptake of IL-23 inhibitors is expected to accelerate. Strategic marketing efforts, patient support programs, and increased payer acceptance are contributing to their growing presence in treatment guidelines, reinforcing the trajectory of sustained adoption for Tremfya and its counterparts in the coming years. This trend reflects a broader shift in autoimmune disease management toward precision-targeted biologics that prioritize sustained remission, minimal side effects, and improved patient convenience.
In this report, the Global Tremfya Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Tremfya Market.
Global Tremfya Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: